T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.05% |
| 2 | Consumer Discretionary | 13.82% |
| 3 | Financials | 13.14% |
| 4 | Industrials | 11.9% |
| 5 | Technology | 9.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1726
JetBlue
JBLU
$2.19B
| $995K | ﹤0.01% |
51,681
+9,990
| +24% | +$170K |
|
|
SUSQ
1727
DELISTED
SUSQUEHANNA BANCSHARES INC
SUSQ
| $993K | ﹤0.01% |
72,418
+25,500
| +54% | +$339K |
|
1728
Delek US
DK
$4.18B
| $990K | ﹤0.01% |
24,900
-13,000
| -34% | -$430K |
|
1729
Silgan Holdings
SLGN
$4.46B
| $989K | ﹤0.01% |
34,040
-4,200
| -11% | -$117K |
|
1730
Idacorp
IDA
$8.16B
| $988K | ﹤0.01% |
15,710
| – | – |
|
1731
Groupon
GRPN
$894M
| $986K | ﹤0.01% |
6,841
-600
| -8% | -$92K |
|
|
SVU
1732
DELISTED
SUPERVALU Inc.
SVU
| $979K | ﹤0.01% |
12,028
+1,286
| +12% | +$92.2K |
|
|
CY
1733
DELISTED
Cypress Semiconductor
CY
| $979K | ﹤0.01% |
69,389
+18,390
| +36% | +$272K |
|
1734
Cinemark Holdings
CNK
$4.37B
| $978K | ﹤0.01% |
21,700
-9,151
| -30% | -$362K |
|
1735
Invesco Mortgage Capital
IVR
$805M
| $975K | ﹤0.01% |
6,280
+350
| +6% | +$54.5K |
|
1736
Hanover Insurance
THG
$7.77B
| $974K | ﹤0.01% |
13,420
| – | – |
|
1737
Deluxe
DLX
$1.11B
| $972K | ﹤0.01% |
14,028
+1,700
| +14% | +$111K |
|
|
SFG
1738
DELISTED
STANCORP FINL GRP
SFG
| $967K | ﹤0.01% |
14,100
| – | – |
|
1739
Fair Isaac
FICO
$24B
| $964K | ﹤0.01% |
10,869
-1,312
| -11% | -$106K |
|
1740
CDW
CDW
$17.8B
| $961K | ﹤0.01% |
25,800
+2,800
| +12% | +$102K |
|
1741
Element Solutions
ESI
$9.51B
| $955K | ﹤0.01% |
37,200
+13,100
| +54% | +$315K |
|
|
IDTI
1742
DELISTED
Integrated Device Technology I
IDTI
| $955K | ﹤0.01% |
47,700
+8,700
| +22% | +$171K |
|
|
MZTI
1743
The Marzetti Company
MZTI
$3.22B
| $952K | ﹤0.01% |
10,000
+3,600
| +56% | +$330K |
|
|
ABMD
1744
DELISTED
Abiomed Inc
ABMD
| $952K | ﹤0.01% |
13,300
+3,300
| +33% | +$179K |
|
1745
WaFd
WAFD
$2.81B
| $951K | ﹤0.01% |
43,610
+5,200
| +14% | +$110K |
|
1746
MSC Industrial Direct
MSM
$6.77B
| $939K | ﹤0.01% |
13,000
| – | – |
|
1747
Kennametal
KMT
$2.32B
| $937K | ﹤0.01% |
27,800
+4,500
| +19% | +$152K |
|
1748
CubeSmart
CUBE
$9.4B
| $935K | ﹤0.01% |
38,700
+4,900
| +14% | +$118K |
|
|
FUEL
1749
DELISTED
Rocket Fuel Inc.
FUEL
| $929K | ﹤0.01% |
100,961
-23,880
| -19% | -$289K |
|
1750
Regal Rexnord
RRX
$11.4B
| $927K | ﹤0.01% |
11,600
| – | – |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.